Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers

被引:120
作者
Benedek, IH
Joshi, AS
Pieniaszek, HJ
King, SYP
Kornhauser, DM
机构
[1] DUPONT MERCK PHARMACEUT CO,STINE HASKELL RES CTR,DRUG METAB & PHARMACOKINET SECT,NEWARK,DE 19714
[2] DUPONT MERCK PHARMACEUT CO,CLIN RES & DEV DEPT,NEWARK,DE 19714
关键词
D O I
10.1002/j.1552-4604.1995.tb04044.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Data describing the pharmacokinetics and pharmacodynamics of low dose aspirin (acetylsalicylic acid; ASA) are limited. This single-center study was designed to determine the rate and extent of oral absorption of 80-mg ASA tablets in healthy, young male subjects and to assess the intra- and inter-subject variability of ASA pharmacokinetics and platelet aggregation effects. Ten subjects each received a single, open-label, oral 80-mg ASA dose on three separate days. Each dose was separated by a 2-week washout interval. Blood samples for pharmacokinetic determinations of ASA and its metabolite, salicylic acid (SA) and platelet aggregation studies were obtained at scheduled timepoints before and up to 24 hours after each dose, Peak plasma ASA levels of 1 mu g/mL were achieved within 30 minutes. Peak plasma SA levels of approximately 4 mu g/mL were attained in 1 hour. The terminal half-lives (t(1/2)) of ASA and SA were 0.4 and 2.1 hours, respectively Both ASA and SA pharmacokinetics and the platelet aggregation response to ASA exhibited considerable intra- and inter-subject variability. Inhibition of platelet aggregation was found to relate with ASA area under the plasma concentration versus time curve (AUC).
引用
收藏
页码:1181 / 1186
页数:6
相关论文
共 15 条
[1]   PHARMACOKINETICS OF LOW-DOSE ORAL MODIFIED RELEASE, SOLUBLE AND INTRAVENOUS ASPIRIN IN MAN, AND EFFECTS ON PLATELET-FUNCTION [J].
BOCHNER, F ;
WILLIAMS, DB ;
MORRIS, PMA ;
SIEBERT, DM ;
LLOYD, JV .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 35 (03) :287-294
[2]   AGGREGATION OF BLOOD PLATELETS BY ADENOSINE DIPHOSPHATE AND ITS REVERSAL [J].
BORN, GVR .
NATURE, 1962, 194 (4832) :927-&
[3]  
CHOW SC, 1990, BIOMED J, V5, P597
[4]  
FitzGerald G A, 1992, Ann Epidemiol, V2, P529
[5]   ASPIRIN AND OTHER ANTIPLATELET AGENTS IN THE SECONDARY AND PRIMARY PREVENTION OF CARDIOVASCULAR-DISEASE [J].
HENNEKENS, CH ;
BURING, JE ;
SANDERCOCK, P ;
COLLINS, R ;
PETO, R .
CIRCULATION, 1989, 80 (04) :749-756
[6]   ESTIMATION OF VARIANCE FOR HARMONIC MEAN HALF-LIVES [J].
LAM, FC ;
HUNG, CT ;
PERRIER, DG .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1985, 74 (02) :229-231
[7]   EFFECTS OF ASPIRIN ON PLATELET-AGGREGATION AS A FUNCTION OF DOSAGE AND TIME [J].
PACCIORETTI, MJ ;
BLOCK, LH .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 27 (06) :803-809
[8]   DOSE-RELATED KINETICS OF ASPIRIN - PRESYSTEMIC ACETYLATION OF PLATELET CYCLOOXYGENASE [J].
PEDERSEN, AK ;
FITZGERALD, GA .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (19) :1206-1211
[9]   POWER OF THE 2 ONE-SIDED TESTS PROCEDURE IN BIOEQUIVALENCE [J].
PHILLIPS, KF .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1990, 18 (02) :137-144
[10]   ASPIRIN IN CARDIOVASCULAR-DISEASE [J].
REILLY, IAG ;
FITZGERALD, GA .
DRUGS, 1988, 35 (02) :154-176